Vertex Pharmaceuticals Inc (VRTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Key Insights
Critical company metrics and information
Share Price
$458.93Market Cap
$118.19 BillionTotal Outstanding Shares
257.53 Million SharesTotal Employees
5,400Dividend
No dividendIPO Date
July 31, 1991SIC Description
Pharmaceutical PreparationsHomepage
https://www.vrtx.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-842.60 Million |
| Net Cash Flow From Investing Activities | $-3.83 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-3.83 Billion |
| Net Cash Flow From Operating Activities | $-842.60 Million |
| Net Cash Flow, Continuing | $-5.90 Billion |
| Net Cash Flow | $-5.87 Billion |
| Exchange Gains/Losses | $32.10 Million |
| Net Cash Flow From Financing Activities | $-1.22 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-1.22 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-479.80 Million |
| Other Operating Expenses | $7.97 Billion |
| Income/Loss From Continuing Operations Before Tax | $259.60 Million |
| Cost Of Revenue | $1.48 Billion |
| Basic Earnings Per Share | $1.85 |
| Costs And Expenses | $10.90 Billion |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Net Income/Loss | $-479.80 Million |
| Income Tax Expense/Benefit | $739.40 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Revenues | $10.63 Billion |
| Basic Average Shares | $258.10 Million |
| Benefits Costs and Expenses | $10.37 Billion |
| Selling, General, and Administrative Expenses | $1.46 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $-479.80 Million |
| Gross Profit | $9.15 Billion |
| Diluted Average Shares | $258.20 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Net Income/Loss Attributable To Parent | $-479.80 Million |
| Operating Income/Loss | $-270.40 Million |
| Operating Expenses | $9.42 Billion |
| Diluted Earnings Per Share | $1.90 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Commitments and Contingencies | $0.00 |
| Intangible Assets | $831.60 Million |
| Other Non-current Assets | $11.60 Billion |
| Equity Attributable To Parent | $15.63 Billion |
| Inventory | $1.08 Billion |
| Noncurrent Liabilities | $2.64 Billion |
| Equity | $15.63 Billion |
| Assets | $22.24 Billion |
| Liabilities And Equity | $22.24 Billion |
| Current Assets | $9.80 Billion |
| Liabilities | $6.61 Billion |
| Other Current Assets | $8.72 Billion |
| Noncurrent Assets | $12.44 Billion |
| Other Current Liabilities | $3.58 Billion |
| Current Liabilities | $3.97 Billion |
| Accounts Payable | $395.80 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Vertex Pharmaceuticals Inc (VRTX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.